CD8A and glioblastoma: In this context, a recent study showed that, upon stimulation with IL13Rα2 glioblastoma cells, CD8+ CAR T cells exhibited a pronounced, but only transient, effector function, becoming rapidly exhausted; in contrast, CD4+ CAR T cells persisted after tumor challenge and sustained their effector potency [386].